抄録
The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 481-487 |
| ページ数 | 7 |
| ジャーナル | International Journal of Pharmaceutics |
| 巻 | 565 |
| DOI | |
| 出版物ステータス | 出版済み - 6 30 2019 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science
これを引用
Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect. / Yoshikawa, Takuma; Mori, Yukina; Feng, Haitao; Phan, Khanh Quoc; Kishimura, Akihiro; Kang, Jeong Hun; Mori, Takeshi; Katayama, Yoshiki.
：: International Journal of Pharmaceutics, 巻 565, 30.06.2019, p. 481-487.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Rapid and continuous accumulation of nitric oxide-releasing liposomes in tumors to augment the enhanced permeability and retention (EPR) effect
AU - Yoshikawa, Takuma
AU - Mori, Yukina
AU - Feng, Haitao
AU - Phan, Khanh Quoc
AU - Kishimura, Akihiro
AU - Kang, Jeong Hun
AU - Mori, Takeshi
AU - Katayama, Yoshiki
PY - 2019/6/30
Y1 - 2019/6/30
N2 - The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.
AB - The modulation of blood flow to tumors is a prominent strategy for improving the tumor accumulation of nanomedicines, resulting from the enhanced permeability and retention (EPR) effect. We previously reported a promising EPR enhancer—a nitric oxide (NO) donor-containing liposome (NO-LP)—which showed enhanced accumulation in tumor tissue. Herein, we study NO-LP in greater detail to clarify its practical use as an EPR enhancer. NO-LP was found to have advantages as a NO donor, including the ability to maintain NO donation over long periods of time, and a constant rate of NO-release irrespective of the environmental pH. NO-LP showed rapid accumulation in tumor tissue after injection (1 h), and then accumulation was continuously enhanced until 48 h. Enhanced NO-LP accumulation was observed specifically in tumor, while the accumulation in other organs remained relatively unchanged. The results obtained show the promising features of NO-LP as an EPR enhancer.
UR - http://www.scopus.com/inward/record.url?scp=85065717913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065717913&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2019.05.043
DO - 10.1016/j.ijpharm.2019.05.043
M3 - Article
VL - 565
SP - 481
EP - 487
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
SN - 0378-5173
ER -